The article is a topical literature review of the place of percutaneous coronary interventions in the structure of elective revascularisation procedures, preoperative preparation of patients with stable ischaemic heart disease before percutaneous coronary intervention, the prospects of the technique, taking into account the latest advances in intervention cardiology (intravascular methods for assessing the hemodynamic significance of stenosis, drug eluting stents). Modern data of the early and long-term results of percutaneous coronary intervention are presented, the predictable potentially modifiable risks of adverse events are described, and ways to correct them are discussed. The results of randomised studies comparing the effectiveness of different approaches for managing patients with stable coronary heart disease (medical therapy, percutaneous coronary intervention) are presented, and prospects for using new drugs to improve the early and late outcomes of endovascular revascularisation are discussed.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Petrosyan KV. Report on the scientific and practical work of the Department of X-ray surgical methods for the study and treatment of heart and vascular diseases for 2018. Byulleten’ NTSSSKH im. A.N. Bakuleva RAMN. Serdechno-sosudistyye zabolevaniya. 2019;20(5):427–33. Russian. https://doi.org/10.24022/1810-0694-2019-20-5-427-433
2. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery. Eur Heart J. 2013;34:2949–3003. https://doi.org/10.1093/eurheartj/eht296
3. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394
4. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372 (13):1204–12. https://doi.org/10.1056/NEJMoa1415447
5. Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016;388(10061):2743–52. https://doi.org/10.1016/S0140-6736(16)32052-9
6. Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-year outcomes of the PRECOMBAT study. J Am Coll Cardiol. 2015;65(20):2198–206. https://doi.org/10.1016/j.jacc.2015.03.033
7. Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with threevessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35(40):2821–30. https://doi.org/10.1093/eurheartj/ehu213
8. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 2014;174(2):223–30. https://doi.org/10.1001/jamainternmed.2013.12844
9. Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174(2):232–40. https://doi.org/10.1001/jamainternmed.2013.12855
12. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394
13. Windecker S, Neumann F-J, Jüni P, Sousa-Uva M, Falk V. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):204–12. https://doi.org/10.1093/eurheartj/ehy532
14. Protopopov АV, Alekyan BG. New knowledge, new horizons – results of up-to-date research in the field of endovascular treatment of coronary heart disease (by the materials of ТСТ Congress 2018). Russ J Endovasc Surg. 2018;5(4):384–401. Russian. https://doi.org/10.24183/2409-4080-2018-5-4-384-401
15. Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F, Clemmensen PM, et al. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017;52(2):206–17. https://doi.org/10.1093/ejcts/ezx115
16. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859. https://doi.org/10.1136/bmj.g3859
17. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16. https://doi.org/10.1056/NEJMoa070829
18. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Investigators. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://doi.org/10.1016/S0140-6736(17)32714-9
24. Argunova YuA, Trubnikova OA, Kagan ES, Barbarash OL. The conneetion of preoperative adherenüe to treatment with the risk of development of early postoperative cognitive dysfunction in patients undergone coronary artery bypass grafting. Russ Cardiol Bull. 2017;12(2):54–9. Russian.
25. Maleva OV, Trubnikova OA, Kuprijanova TV, Kuhareva IN, Barbarash OL. Adherence to treatment in patients with ischaemic heart disease depending on their cognitive status. Lechashhij Vrach. 2017;(10):53. Russian.
26. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA Study). Am J Cardiol. 2007;100(8): 1245–8. https://doi.org/10.1016/j.amjcard.2007.05.044
27. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A Comparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J. 2005;26(24):2664–72. https://doi.org/10.1093/eurheartj/ehi482
28. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009; 54(5):810–9. https://doi.org/10.1053/j.ajkd.2009.03.022
29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocar-dial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2004;110(6):674–8. https://doi.org/10.1161/01.CIR.0000137828.06205.87
31. Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015;8(3):414–23. https://doi.org/10.1016/j.jcin.2014.10.015
32. Pourhosseinia H, Lashkaria R, Aminorroayaa A, Soltania D, Jalalia A, Tajdini M. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. Int J Cardiol Heart Vasc. 2019;22:96–101. https://doi.org/10.1016/j.ijcha.2018.12.003
33. Vershinina EO, Repin AN, Udut VV, Timofeev MS. Prevention of periprocedural kidney ingury by loading doses of statins in elective percutaneous сeronary interventions. Kardiologiia. 2018;58(S5):20–9. Russian. https://doi.org/10.18087/cardio.2459
34. Vershinina EO, Repin AN. Contrast-induced nephropathy after elective percutaneous coronary interventions. Sib Med Zhurn (t. Tomsk). 2016;31(3):61–7. Russian.
35. Wang XL, Zhang T, Hu LH, Sun SQ, Zhang WF, Sun Z, et al. Comparison of effects of different statins on contrast-induced acute kidney injury in rats: histopathological and biochemical findings. Oxid Med Cell Longev. 2017;2017: 1–10. https://doi.org/10.1155/2017/6282486
36. Pristrom AM, Pyrochkin AV, Chernoglaz PF, Borisenko TD, Gavrosh TS, Dechko SV, et al. Rosuvastatin (mertenil®) in prevention of contrast-induced nephropathy in elective percutaneous coronary intervention. Meditsinskie novosti. 2016;(1):27–32. Russian.
38. Panchenko EP. Have we shifted our paradigm of clopidogrel as a mandatory drug in treatment of cardiological patients after the introduction of more powerful antiagregants? Atherothrombosis. 2017;(2):32–42. Russian. https://doi.org/10.21518/2307-1109-2017-2-32-42
42. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940
43. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939
44. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35. https://doi.org/10.1177/2047487318825350
45. Warren J, Nanayakkara S, Andrianopoulos N, Brennan A, Dinh D, Yudi M, et al. Impact of pre-procedural blood pressure on long-term outcomes following percutaneous coronary intervention. J Am Coll Cardiol. 2019;73(22):2846–55. https://doi.org/10.1016/j.jacc.2019.03.493
46. Ignatova YS, Karetnikova VN, Kochergina AM, Gruzdeva OV, Khorlampenko AA, Barbarash OL. Diagnosis and correction of carbohydrate metabolism disorders before elective transcutaneous coronary intervention in conditions of real-life clinical practice. Serdce. 2017;16(4):253–9. Russian. https://doi.org/10.18087/rhj.2017.4.2365
47. Dedov II, Shestakova MV, Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Melitus. 2016;19(2):104-12. Russian. https://doi.org/10.14341/DM2004116-17
48. Dedov II, Shestakova MV, Mayorov AY, Vikulova OK, Galstyan GR, Kuraeva TL, et al. 8th edition. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus. 2017;18(1S):1–112. Russian. https://doi.org/10.14341/dm20151s1-112
49. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russian Journal of Cardiology. 2014;19(3):7–61. Russian.
50. Golukhova EZ, Kuznetsova EV. Myocardial revascularization in patients with type 2 diabetes mellitus: An overview of modern techniques. Diabetes Mellitus. 2016;19(5):406–13. Russian. https://doi.org/10.14341/DM8031
51. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J. 2008;156(3):528–36. https://doi.org/10.1016/j.ahj.2008.05.015
52. Kassaian SE, Goodarzynejad H, Boroumand MA, Salarifar M, Masoudkabir F, Mohajeri-Tehrani MR, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11:82. https://doi.org/10.1186/1475-2840-11-82
53. Pomeshkina SA, Borovik IV, Krupyanko EV, Zavirilina IN, Barbarash OL. Compliance with drug therapy in patients with coronary artery disease undergoing coronary artery bypass grafting. Sib Med Zhurn (t. Tomsk). 2013;28(4):71–6. Russian.
54. Iijima R, Nakamura M, Matsuyama Y, Muramatsu T, Yokoi H, Hara H, et al. Effect of optimal medical therapy before procedures on outcomes in coronary patients treated with drug-eluting stents. Am J Cardiol. 2016;118(6):790–6. https://doi.org/10.1016/j.amj-card.2016.06.050
55. Ignatova YuS, Karetnikova VN, Kochergina AM, Gruzdeva OV, Khorlampenko AA, Zagorodnikov NI, et al. Diagnostic value of markers of carbohydrate metabolism disorders in patients with coronary artery disease before planned percutaneous coronary intervention. Creat Cardiol. 2018;12(3):211–24. Russian. https://doi.org/10.24022/1997-3187-2018-12-3-211-224